Zymeworks was a private biopharmaceutical company based in Vancouver, Canada. The company leveraged its novel platforms to design and develop best-in-class bi-specific antibody and ADC treatments. Its lead program, zanidatamab, a bispecific antibody targeting HER2-expressing cancers. In 2017, Zymeworks went public on the NYSE under the ticker ZYME.
Solid tumors
CTI LSF I
Lead
Director
January 22, 2009
IPO on the NYSE
Series A
Zymeworks had two innovative rationale design platforms – Azymetric and Zymelink, for rationale design of antibody-based treatments
April 26, 2016
June 23, 2009
December 5, 2017
March 22, 2016
November 27, 2017
January 8, 2016
